Stanford Advisors

  • JW Day, Postdoctoral Faculty Sponsor

Contact

  • Academic
    bradley5@stanford.edu
    University - Scholar Department: Adult Neurology Position: Postdoctoral Scholar

Additional Info

All Publications

  • A Biosynthetic Approach for CpG Methylation of AAV Expression Cassettes Huellen, F., Patil, R., Hamilton, B. A., Wright, J. CELL PRESS. 2023: 113-114

    View details for Web of Science ID 001045144200211

  • A Human PBMC Assay of Type 1 Interferon Responses to Closely Related AAV Vectors Hamilton, B. A., Patil, R., Kim, S., Day, J. W., Wright, J. CELL PRESS. 2023: 76

    View details for Web of Science ID 001045144200141

  • Methylation of CpG Dinucleotides in AAV Vector Plasmids Reduces TLR9 Immune Activation Patil, R., Hamilton, B., Perriman, R., Wright, J. CELL PRESS. 2022: 66-67

    View details for Web of Science ID 000794043700125

  • ITRS FROM AAV SEROTYPES DIFFERENTIALLY STIMULATE INNATE IMMUNE SIGNALING THROUGH TLR9 Hamilton, B., Patil, R., Wright, F. ELSEVIER SCIENCE INC. 2022: S92

    View details for Web of Science ID 000890643400145

  • Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes. Frontiers in immunology Hamilton, B. A., Wright, J. F. 2021; 12: 675897

    Abstract

    Host immune responses that limit durable therapeutic gene expression and cause clinically significant inflammation remain a major barrier to broadly successful development of adeno-associated virus (AAV)-based human gene therapies. In this article, mechanisms of humoral and cellular immune responses to the viral vector are discussed. A perspective is provided that removal of pathogen-associated molecular patterns in AAV vector genomes to prevent the generation of innate immune danger signals following administration is a key strategy to overcome immunological barriers.

    View details for DOI 10.3389/fimmu.2021.675897

    View details for PubMedID 34084173

https://orcid.org/0000-0002-5475-0785